BGPT: Paper Review: An RNA transmethylation pathway governs kidney nephrogenic potential

Explore by Goal

Quick Explanation Copied

Paper-at-a-glance (skeptical, evidence-weighted)

This work proposes and tests a methionine → SAM → METTL3 (RNA transmethylation) → LRPPRC → mitochondrial metabolism → nephron progenitor differentiation/nephrogenesis axis, claiming both necessity (methionine restriction, METTL3 inhibition/KO) and sufficiency (SAM or METTL3 activation) in mouse nephron progenitors, plus functional downstream rescue via LRPPRC blockade (GAA). Evidence includes metabolomics, SAM/METTL3 perturbations, in vivo nephron counts and eGFR, and METTL3–LRPPRC mRNA association with LRPPRC protein/OXPHOS phenotypes. Key uncertainty: many “direct” claims rely on pharmacology plus binding correlations; the paper acknowledges additional METTL3 targets beyond Lrpprc.

Long Explanation

Review of: An RNA transmethylation pathway governs kidney nephrogenic potential

Core claim: a methionine-derived SAM “transmethylation state” sensed by METTL3 controls early nephron progenitor differentiation/nephrogenesis, via LRPPRC and mitochondrial metabolic remodeling.

VISUAL MAP: proposed causal chain

Evidence basis: metabolite/MAT2A/METTL3/METTL14/m6A increases during differentiation; SAM drives differentiation; METTL3 inhibition/KO blocks; Lrpprc is an m6A-associated/metabolically linked target whose inhibition blocks SAM/METTL3 nephrogenic effects.

FIGURE 1 (reconstructed numbers from paper): neonatal kidney function gain with submaximal SAM / METTL3 activation

Interpretation constraints: these bars summarize a specific reported timepoint and unit scheme; the paper also reports dose-dependence (e.g., 50 mg/kg SAM not effective) and mechanisms linking to NPC niche expansion.

FIGURE 2 (reconstructed): fraction of induced double-positive NPCs (SIX2-eGFP & PAX8)

Major skepticism: the paper reports “nearly 70%” for SAM and M3A at P4.5 but also gives additional quantitative niche metrics (e.g., cluster counts); the exact SAM vs M3A percentage may not be fully numerically specified in the excerpted text here, so the plot should be treated as directional.

1) What the authors actually show (evidence-weighted)

A. Early differentiation correlates with SAM–METTL3 axis activation

In vitro (NPC fate transition model): differentiation conditions show >2-fold increases in methionine and SAM, increased MAT2A, and increased METTL3/METTL14; m6A levels rise in parallel (reported in Fig. 1 panels).
In vivo relevance (E16.5 mouse niches + human fetal scRNA-seq): higher signals for MAT2A, METTL3, m6A, and METTL14 in pre-tubular aggregate-like differentiation contexts; single-cell atlas indicates enrichment of writer/Metabolism genes in differentiation-committed/tubular precursors.

B. Necessity: removing transmethylation state or METTL3 blocks differentiation/nephrogenesis

SAM drives differentiation; SAH does not: SAM supplementation counteracts renewal from CHIR, while SAH fails to promote differentiation in the cited culture experiments (suggesting SAM-state sufficiency rather than generalized methylation byproduct effects).
METTL3 inhibition and genetic KO: METTL3 inhibitor STM2457 is described to counteract SAM-induced differentiation and preserve SIX2 identity; Six2-Cre Mettl3 knockout reduces nephron count and delays/blocks formation of PAX8+ differentiated structures.
Timing window: Wnt4-Cre–restricted deletion in renal vesicle/pre-tubular structures is reported to have no effect on nephrogenesis, implying METTL3 is critical during earlier NPC state transitions.

C. Sufficiency: increasing SAM/METTL3 activity promotes nephron endowment

Ex vivo rescue: methionine-depleted E12.5 kidneys show reduced nephron differentiation and ureteric branching, but SAM supplementation restores nephrogenesis while SAH does not.
In vivo neonatal window: low/submaximal dosing (25 mg/kg SAM; 2.17 mg/kg M3A) increases kidney weight-to-body weight ratio and glomerular number; excessive activation (50 mg/kg SAM) is reported not to yield the same benefit.

2) Mechanism: LRPPRC as a METTL3 downstream node

Target discovery: RNA-Seq/MeRIP-seq in Six2-Cre Mettl3-KO kidneys identifies mitochondrial metabolism gene downregulation and an m6A landscape change, with Lrpprc highlighted as a candidate transcript.
Direct association evidence: METTL3 immunoprecipitation enriched LRPPRC/Lrpprc mRNA up to ~300-fold vs IgG controls in both human and mouse epithelial contexts.
Translation/protein link: LRPPRC protein is reported lower in Six2-Cre Mettl3-KO kidneys and higher in Mettl3-OE kidneys, with Lrpprc transcript levels largely unchanged—interpreted as METTL3 affecting translational efficiency rather than transcription.
Functional epistasis via pharmacology: LRPPRC inhibition using GAA is reported to block LRPPRC/OXPHOS/MitoTracker signal and to prevent SAM/M3A/CHIR-induced differentiation outcomes in NPC cultures and nephrogenesis outcomes in neonates; co-treatment with SAM+GAA or M3A+GAA inhibits the pro-nephrogenic effects.

Mechanistic skepticism

The paper makes a direct mechanistic case for Lrpprc, but key pieces are still partly pharmacology- and correlation-dependent: (i) RNA binding ≠ catalytic methylation at the functional site; (ii) GAA can have off-target or broader pathway effects (the paper itself flags this possibility); (iii) METTL3 likely has additional targets contributing to mitochondrial biogenesis, so Lrpprc may be necessary for part of the phenotype rather than the whole mechanism.

3) Quality check (skeptical audit)

Strengths (high confidence)

Orthogonal perturbations: nutrient (methionine depletion), cofactor supplementation (SAM/SAH), enzyme inhibition (METTL3 inhibitor), enzyme activation (M3A), and conditional genetics (Mettl3 KO, stage-specific Cre) are combined to support necessity/sufficiency and timing-window logic.
Functional endpoints: nephron counts and eGFR are used, not just marker expression, which strengthens biological relevance.

Red flags / blind spots (what could break the causal story)

Pharmacology specificity: multiple small molecules are used (SAM, STM2457, M3A, GAA). The causal statements about direct pathway logic may fail if any compound has off-target effects that mimic/oppose METTL3 or LRPPRC-specific functions.
“Direct target” vs “functional mediator”: METTL3 binding enrichment does not prove site-specific catalytic methylation of the Lrpprc transcript produces the reported protein/OXPHOS shifts. A stronger causal chain would require methylation-site-specific perturbations or orthogonal genetic epistasis (e.g., Lrpprc KO/conditional rescue) specifically within the same NPC window.
Observer bias / blinding: the methods section states investigators were not blinded to treatment or genotype. This does not automatically invalidate the data, but it does increase risk of measurement/quantification bias for subjective endpoints (e.g., niche counting, certain image-based quantifications).
Species translation gap: the paper uses mouse NPC nephrogenesis and only indirectly links relevance to human development (staining + fetal scRNA-seq enrichment). That supports plausibility but not proof of equivalent pathway control in humans.

4) Context: what this adds relative to known METTL3 biology

The paper’s mechanistic backbone leverages known structural/biochemical understanding that METTL3 is the catalytic core for m6A methylation and binds SAM; METTL14 supports and scaffolds the writer complex. The novelty here is developing kidney causality: linking that enzymatic axis to a defined developmental fate transition and nephron endowment outcome in a controlled manner across nutrient/metabolic states.

5) Practical next-step experiments that would most falsify/strengthen the paper

Genetic epistasis for Lrpprc: conditional Lrpprc deletion in Six2+ NPCs during the critical window, followed by SAM/M3A responsiveness tests. If SAM/M3A fails to increase nephron endowment similarly to METTL3 KO (and if Lrpprc overexpression rescues the METTL3 KO phenotype), the Lrpprc branch becomes much more causally grounded.
Site-specific methylation mechanism: use orthogonal mapping (beyond total m6A ELISA/dot blot) to identify whether Lrpprc transcript methylation changes at specific motifs/sites under SAM/METTL3 activation and whether those sites are necessary for protein upregulation. (This directly tests whether METTL3’s catalytic action at Lrpprc explains the mechanism.)
Off-target quantification: pharmacology control experiments that quantify whether STM2457/M3A/GAA perturb the pathway through independent readouts (e.g., global m6A occupancy in NPCs; mitochondrial transcriptome changes) and whether the dose-response curve correlates with on-target biochemical changes.

Author review links (bespoke)

Feedback:

Updated: March 30, 2026